| NIPPON-SHINYAKU |
NIPPON-SHINYAKU |
92%
|
The Company concluded that each of the distinct units of account identified under the Nippon Shinyaku Collaboration Agreement should be accounted for as revenue under ASC 606, as Nippon Shinyaku is d… |
| NOVARTIS-GENE-THERAPIES |
NOVARTIS-GENE-THERAPIES |
92%
|
Two customers (Novartis Gene Therapies and Nippon Shinyaku) accounted for approximately 99% of our total revenues for the year ended December 31, 2025. |
| NOVARTIS-GENE-THERAPIES-INC |
NOVARTIS-GENE-THERAPIES-INC |
85%
|
the licensee. Royalty revenue to date consists primarily of royalties on net sales of Zolgensma and Itvisma, which are licensed products under the Company’s license agreement with Novartis Gene Thera… |
| NVSEF |
Novartis AG |
85%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from RGNX graph: . (Novartis Gene Therapies), a wh… |
| NVSEF |
Novartis AG |
85%
|
. (Novartis Gene Therapies), a wholly owned subsidiary of Novartis AG (Novartis), for the development and commercialization of treatments for spinal muscular atrophy (SMA). The Company recognizes roy… |
| DNLI |
Denali Therapeutics Inc. |
72%
|
Reciprocal relationship from DNLI graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one… |
| DNLI |
Denali Therapeutics Inc. |
72%
|
atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| FDMT |
4D Molecular Therapeutics, Inc. |
72%
|
atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| FDMT |
4D Molecular Therapeutics, Inc. |
72%
|
Reciprocal relationship from FDMT graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will exp… |
| OTLK |
Outlook Therapeutics, Inc. |
72%
|
atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| OTLK |
Outlook Therapeutics, Inc. |
72%
|
Reciprocal relationship from OTLK graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from OTLK graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one… |
| PTCT |
PTC Therapeutics, Inc. |
72%
|
issued European patent that will expire in 2036, one pending PCT application and ten PCTs that have entered national stage for which any issued U.S. or European patents would expire in 2034, 2036, 20… |
| PTCT |
PTC Therapeutics, Inc. |
72%
|
Reciprocal relationship from PTCT graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from PTCT g… |
| RARE |
Ultragenyx Pharmaceutical Inc. |
72%
|
atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| RARE |
Ultragenyx Pharmaceutical Inc. |
72%
|
Reciprocal relationship from RARE graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will exp… |
| RCKT |
Rocket Pharmaceuticals, Inc. |
72%
|
f the Company’s operating leases: As of December 31, 2025 2024 Weighted-average remaining lease term (years) 9.8 10.3 Weighted-average discount rate 5.7 % 5.7 % The following table presents a reconci… |
| RCKT |
Rocket Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from RCKT graph: Reciprocal relationship from RGNX graph: f the Company’s operating leases: As of December 31, 2025 2024 Weighted-average remaining lease term (years) 9.8 10.3… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from REGN g… |
| SRPT |
Sarepta Therapeutics, Inc. |
72%
|
atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| SRPT |
Sarepta Therapeutics, Inc. |
72%
|
Reciprocal relationship from SRPT graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one… |
| TNYA |
Tenaya Therapeutics, Inc. |
72%
|
Reciprocal relationship from TNYA graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will exp… |
| TNYA |
Tenaya Therapeutics, Inc. |
72%
|
atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| TSHA |
Taysha Gene Therapies, Inc. |
72%
|
atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| TSHA |
Taysha Gene Therapies, Inc. |
72%
|
Reciprocal relationship from TSHA graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will exp… |
| ABBV |
AbbVie Inc. |
62%
|
Reciprocal relationship from ABBV graph: Reciprocal relationship from RGNX graph: hich represents consideration received or unconditionally due from licensees and collaboration partners for performan… |
| ABBVIE-GLOBAL-ENTERPRISES-LTD |
ABBVIE-GLOBAL-ENTERPRISES-LTD |
62%
|
hich represents consideration received or unconditionally due from licensees and collaboration partners for performance obligations that have not yet been satisfied by the Company. Unsatisfied perfor… |
| ABEONA-THERAPEUTICS-INC |
ABEONA-THERAPEUTICS-INC |
62%
|
hich represents consideration received or unconditionally due from licensees and collaboration partners for performance obligations that have not yet been satisfied by the Company. Unsatisfied perfor… |
| GLAXOSMITHKLINE-LLC |
GLAXOSMITHKLINE-LLC |
62%
|
In May 2016, the Company entered into an operating lease for office space in New York, New York (the New York Lease), which has since been amended to include additional office space and extend the te… |
| HEALTHCARE-ROYALTY-MANAGEMENT-LLC |
HEALTHCARE-ROYALTY-MANAGEMENT-LLC |
62%
|
value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for assets and liabilities categorized in Level 3. The level within th… |
